First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma
The antitumor activity of immunotherapy is strongly influenced by the presence of driver gene mutations/translocations. For this reason, knowledge of the predictive value of specific genetic alterations in relation to anti-PD(L)1 activity is highly useful for the clinical decision making process in...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2025-01-01
|
| Seri Bilgileri: | Current Oncology |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/1718-7729/32/2/68 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|